IMRN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

IM

Mkt Cap

$7.9M

Volume

19.09K

Loading chart

IM

IMRNImmuron Limited American Depositary Shares

IMRN

Pay with—

Available Balance0.00

IM

Mkt Cap

$7.9M

Volume

19.09K

Next Earnings

N/A

Chart Earnings News About Insider Filings

Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior YearImmuron Limited announced FY26 unaudited sales of AUD$7.7 million, up 6% year-over-year, driven by growth in Australia (+10%) and the USA (+7% AUD, +13% USD) for its Travelan® product. Australia's growth was attributed to increased digital marketing, same-store growth, and new retail placements, while US growth benefited from improved Amazon presence and social media initiatives. Canada showed exceptional Q4 growth of 427% on prior comparative period following pipeline fill in FY25, though full-year Canada sales declined 55% due to timing of initial stocking.GlobeNewswire Inc. · Jul 16, 2026

Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering StrategyImmuron Limited has engaged Pullan Consulting to secure a strategic partnership for IMM-529, its investigational polyclonal antibody treatment for Clostridioides difficile infection (CDI). The company has FDA approval for the IND application and is preparing for Phase 2 clinical trials in Australia. Based on market assessments, IMM-529 could generate projected annual revenues of US$400M if efficacious, with potential partnership deals ranging from US$1-50M upfront plus significant milestone payments and royalties.GlobeNewswire Inc. · Jul 6, 2026

Immuron Double Digit 3Q Sales GrowthImmuron Limited announced Q3 sales of AUD$1.5 million, up 16% year-over-year, driven by growth in Australia (+15%), Canada (+82% quarter-over-quarter), and the USA (+1%). The company attributed growth to increased digital marketing, new retail partnerships, and brand awareness initiatives for its Travelan® product across all regions.GlobeNewswire Inc. · Apr 17, 2026

Immuron Reports HY26 Results and Strategic ResetImmuron Limited reported H1 FY26 global sales of AUD$4.2 million with 5% growth and strong U.S. momentum (+17% YoY). The company raised AUD$7.3 million and announced a strategic reset focusing on partnerships to advance its Travelan® and IMM-529 clinical programs. IMM-124E is eligible for FDA end of Phase 2 meeting, while IMM-529 received FDA IND approval for C. difficile treatment.GlobeNewswire Inc. · Feb 25, 2026

Immuron New U.S. Department of Defense Award & Clinical Trial UpdateImmuron Limited receives a U.S. Department of Defense subaward to develop oral therapeutics targeting Campylobacter and Shigella, with plans to produce hyper-immune bovine colostrum products for pre-clinical evaluation and potential military use.GlobeNewswire Inc. · Dec 3, 2025

Immuron IMM-529 IND approved by FDAImmuron Limited received FDA approval for its Investigational New Drug (IND) application for IMM-529, a potential treatment for Clostridioides difficile infection. The company plans to initiate a Phase 2 clinical trial in the first half of 2026, targeting up to 60 subjects with first episode or recurrent CDI.GlobeNewswire Inc. · Nov 5, 2025

Immuron Announces Clinical Trial UpdateImmuron Limited submitted an Investigational New Drug (IND) application to the FDA for IMM-529, targeting Clostridioides difficile infection. The company's Travelan® P2TD study results are delayed until November 2025 due to government shutdown, with potential implications for future dosing strategies.GlobeNewswire Inc. · Oct 31, 2025

Immuron Submits IMM-529 IND to FDAImmuron has submitted an Investigational New Drug (IND) application to the FDA for IMM-529, a potential treatment for Clostridioides difficile infection. The company plans to initiate a Phase 2 clinical trial in 2026, targeting a potential annual revenue of $400M.GlobeNewswire Inc. · Oct 8, 2025

Immuron Letter to Shareholders – Projects UpdateImmuron Limited provides updates on multiple pharmaceutical development projects, including clinical trials for Travelan®, IMM-529, and ProIBS®, with anticipated milestones in late 2025 and potential market opportunities in traveler's diarrhea and infection treatments.GlobeNewswire Inc. · Oct 2, 2025

Immuron partners with InvestorHubImmuron Limited announced a partnership with InvestorHub to create an interactive digital platform for improved investor communication, with plans to share content about upcoming milestones including FDA submission for IMM-529 and clinical trial results for Travelan®.GlobeNewswire Inc. · Aug 27, 2025

to start trading

IM

IMRNImmuron Limited American Depositary Shares

IMRN

Pay with—

Available Balance0.00

Your PositionYou don't own any IMRN yet.

Related Tickers

Earnings